Keyphrases
Diffuse Large B-cell Lymphoma (DLBCL)
100%
Postpartum Hemorrhage
50%
Randomized Controlled Trial
50%
PD-L2
50%
Fibrinogen Concentrate
50%
Lymphoma
34%
Fibrinogen
33%
Programmed Death-ligand 1 (PD-L1)
30%
R-CHOP
28%
Improved Survival
25%
Impacted Fetal Head
25%
COVID-19
25%
Hematological Malignancies
25%
National Cohort Study
25%
Fluorine-18-fluorodeoxyglucose Positron Emission Tomography
25%
Melastatin
25%
B Cell Subtypes
25%
Hospitalized Patients
25%
Cancer Immune Therapy
25%
Remdesivir
25%
Inhibitory Checkpoints
25%
Early Signs
25%
TRP Channels
25%
Clinical Outcomes
25%
Population Pharmacokinetics
25%
Ultrasound Examination
25%
Emergency Caesarean Section
25%
Population Analysis
25%
Activated B Cells
25%
Aggressive non-Hodgkin Lymphoma
25%
Early Change
25%
Effector T Cells
25%
Initial Treatment
25%
Serum interleukin-6
25%
Factor Level
25%
Clinical Assessment
25%
Immunogenic
25%
Preemptive Treatment
25%
L1-L2
25%
Ropivacaine
25%
First-line Therapy
25%
First-in-human
25%
Prognostic Score
25%
Local Infiltration Anesthesia
25%
Prediction Model
25%
Poor Survival
25%
Prognostic Stratification
25%
Immune Modulatory Vaccine
25%
Bilateral Total Knee Arthroplasty
25%
Follicular Lymphoma
25%
Medicine and Dentistry
Diffuse Large B-Cell Lymphoma
100%
Cesarean Section
29%
Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine
28%
Randomized Controlled Trial
25%
Positron Emission Tomography
25%
Fluorodeoxyglucose
25%
DNA (Cytosine 5) Methyltransferase 1
25%
Transient Receptor Potential Channel
25%
Transient Receptor Potential Channel M4
25%
Hematologic Malignancy
25%
Clinical Assessment
25%
Malignant Neoplasm
25%
Population Stratification
25%
Fluorine-18
25%
Fetal Head
25%
B Cell
25%
Focused Ion Beam
25%
Immunotherapy
25%
Lochia
25%
Urinary Retention
25%
Acute Kidney Injury
25%
Bleeding
25%
Fibrinogen Concentrate
25%
Rituximab
16%
International Prognostic Index
16%
Kidney Function
15%
Intensive Care Unit
15%
Catheterization
12%
Bladder
12%
Fibrinogen
12%
Multivariate Analysis
11%
Lactate Dehydrogenase
11%
Overall Survival
10%
Creatinine
10%
Acute Lymphoblastic Leukemia
8%
Blood Transfusion
8%
Cancer Immunization
8%
Lymphoblastic Lymphoma
8%
Cancer
8%
Myeloid Malignancy
8%
Tumor Antigen
8%
Immune Checkpoint Inhibitor
8%
Chimeric Antigen Receptor T-Cell
8%
Lymphoid Malignancy
8%
Progression Free Survival
6%
Clinical Finding
6%
Post-Anesthesia Care Unit
6%
Nurse
6%
Palpation
6%
Fetus Death
6%
